不应将单克隆抗体用于COVID-19治疗：呼吁进行抗病毒药物管理。
Single Monoclonal Antibodies Should Not Be Used for COVID-19 Therapy: A Call for Antiviral Stewardship.
作者信息
Casadevall Arturo, Focosi Daniele, Pirofski Liise-Anne, Shoham Shmuel
机构信息
Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
出版信息
Clin Infect Dis. 2024 Dec 17;79(6):1404-1407. doi: 10.1093/cid/ciae408.
PMID:39115342
Abstract
The COVID-19 pandemic witnessed the greatest deployment of monoclonal antibody (mAb) therapies for an infectious disease, but all were defeated by SARS-CoV-2 evolution. As new mAbs are developed, the infectious disease community needs stewardship practices to reduce emergence of resistance.
摘要
在新冠疫情期间，单克隆抗体（mAb）疗法针对一种传染病进行了最大规模的应用，但所有这些疗法都被新冠病毒的进化击败。随着新的单克隆抗体的研发，传染病领域需要管理措施来减少耐药性的出现。
Zotero 插件